OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
In silico prediction of post-translational modifications in therapeutic antibodies	292
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	217
Correction	120
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	95
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	86
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	85
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	72
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	66
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	61
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	60
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	59
An antibody developability triaging pipeline exploiting protein language models	57
Correction	55
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	46
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	44
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	41
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	38
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	38
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	38
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	36
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	36
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	36
Correction	35
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	34
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	34

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	33
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	30
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	30
Impact of IgG subclass on monoclonal antibody developability	30
Structural and functional characterization of a monoclonal antibody blocking TIGIT	28
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	27
Predicting antibody binders and generating synthetic antibodies using deep learning	27
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	27
Antibodies to watch in 2024	26
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	25
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	24
Quantifying antibody binding: techniques and therapeutic implications	24
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	24
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	23
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	22
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	22
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG ₁ antibody	22
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	21
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	21
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	21
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	21
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	20
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	20
The eIg technology to generate Ig-like bispecific antibodies	20
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	19
In silico proof of principle of machine learning-based antibody design at unconstrained scale	19
Cost and supply considerations for antibody therapeutics	19
Evolution of phage display libraries for therapeutic antibody discovery	18
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	17
A versatile design platform for glycoengineering therapeutic antibodies	16
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	16
Electrostatic properties of human germlines and biodistribution of small biologics	16
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	15
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	15
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	15
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	15
A glyco-engineering approach for site-specific conjugation to Fab glycans	14
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	14
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	14
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	14
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	14
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	14
Leveraging multi-modal feature learning for predictions of antibody viscosity	14
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	13
Engineering death resistance in CHO cells for improved perfusion culture	13
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	13
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	13
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	12
Reduction of monoclonal antibody viscosity using interpretable machine learning	12
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	12

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	12
Structural and biochemical differences between non-catalytic and catalytic antibodies	12
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	12
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	12
Predicting purification process fit of monoclonal antibodies using machine learning	12
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	12
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	11
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	11
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	11
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	11
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	11
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	11
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	11
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	11